Rules-Based Medicine Newswire (Page 9)

Rules-Based Medicine Newswire (Page 9)

Comprehensive Real-Time News Feed for Rules-Based Medicine. (Page 9)

Results 161 - 180 of 1,354 in Rules-Based Medicine

  1. FY2017 EPS Estimates for Myriad Genetics, Inc. Lifted by GabelliRead the original story w/Photo

    Feb 12, 2017 | IntersportsWire

    Myriad Genetics, Inc. - Investment analysts at Gabelli boosted their FY2017 EPS estimates for Myriad Genetics in a research note issued to investors on Wednesday. Gabelli analyst S. Wojda now anticipates that the brokerage will earn $1.05 per share for the year, up from their prior estimate of $1.00.

    Comment?

  2. Q3 2017 Earnings Estimate for Myriad Genetics, Inc. Issued By Jefferies GroupRead the original story w/Photo

    Feb 12, 2017 | Daily Political

    Myriad Genetics, Inc. - Stock analysts at Jefferies Group lowered their Q3 2017 earnings estimates for shares of Myriad Genetics in a report issued on Wednesday. Jefferies Group analyst B. Couillard now anticipates that the brokerage will post earnings of $0.24 per share for the quarter, down from their previous forecast of $0.28.

    Comment?

  3. Clinton Group Inc. Has $948,000 Stake in Myriad Genetics, Inc.Read the original story w/Photo

    Feb 11, 2017 | Daily Political

    Clinton Group Inc. decreased its stake in Myriad Genetics, Inc. by 73.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 46,045 shares of the company's stock after selling 130,158 shares during the period.

    Comment?

  4. Myriad Genetics, Inc. (MYGN) to Post FY2021 Earnings of $2.00 Per Share, Gabelli ForecastsRead the original story w/Photo

    Feb 10, 2017 | Daily Political

    Myriad Genetics, Inc. - Research analysts at Gabelli issued their FY2021 EPS estimates for shares of Myriad Genetics in a note issued to investors on Wednesday. Gabelli analyst S. Wojda anticipates that the firm will post earnings per share of $2.00 for the year.

    Comment?

  5. Myriad Genetics, Inc. to Post Q4 2017 Earnings of $0.29 Per Share, Jefferies Group ForecastsRead the original story w/Photo

    Feb 10, 2017 | IntersportsWire

    Myriad Genetics, Inc. - Analysts at Jefferies Group raised their Q4 2017 EPS estimates for shares of Myriad Genetics in a research note issued to investors on Wednesday. Jefferies Group analyst B. Couillard now expects that the brokerage will earn $0.29 per share for the quarter, up from their previous forecast of $0.28.

    Comment?

  6. 1,108,720 Shares in Myriad Genetics, Inc. (MYGN) Acquired by Russell Investments Group Ltd.Read the original story w/Photo

    Feb 10, 2017 | IntersportsWire

    Russell Investments Group Ltd. purchased a new stake in shares of Myriad Genetics, Inc. during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,108,720 shares of the company's stock, valued at approximately $18,571,000.

    Comment?

  7. FY2017 Earnings Estimate for Myriad Genetics, Inc. (MYGN) Issued By GabelliRead the original story w/Photo

    Feb 10, 2017 | AmericanBankingNews.com

    Myriad Genetics, Inc. - Analysts at Gabelli raised their FY2017 earnings per share estimates for shares of Myriad Genetics in a research note issued to investors on Wednesday. Gabelli analyst S. Wojda now expects that the brokerage will post earnings per share of $1.05 for the year, up from their prior forecast of $1.00.

    Comment?

  8. Q3 2017 EPS Estimates for Myriad Genetics, Inc. (MYGN) Reduced by Jefferies GroupRead the original story w/Photo

    Feb 10, 2017 | IntersportsWire

    Myriad Genetics, Inc. - Jefferies Group cut their Q3 2017 earnings per share estimates for shares of Myriad Genetics in a report issued on Wednesday. Jefferies Group analyst B. Couillard now anticipates that the firm will post earnings per share of $0.24 for the quarter, down from their previous forecast of $0.28.

    Comment?

  9. Gabelli Weighs in on Myriad Genetics, Inc.'s FY2021 EarningsRead the original story w/Photo

    Feb 9, 2017 | AmericanBankingNews.com

    Myriad Genetics, Inc. - Equities researchers at Gabelli issued their FY2021 EPS estimates for shares of Myriad Genetics in a research report issued to clients and investors on Wednesday. Gabelli analyst S. Wojda anticipates that the firm will earn $2.00 per share for the year.

    Comment?

  10. Myriad Genetics, Inc. (MYGN) Shares Gap Up Following Analyst UpgradeRead the original story w/Photo

    Feb 9, 2017 | IntersportsWire

    Myriad Genetics, Inc. 's share price gapped up prior to trading on Thursday after Piper Jaffray Companies raised their price target on the stock to $22.00. The stock had previously closed at $15.35, but opened at $16.52.

    Comment?

  11. Myriad Genetics, Inc. (MYGN) Stock Rating Reaffirmed by Piper Jaffray CompaniesRead the original story w/Photo

    Feb 9, 2017 | IntersportsWire

    's stock had its "neutral" rating restated by equities research analysts at Piper Jaffray Companies in a report released on Tuesday. They currently have a $21.00 price objective on the stock.

    Comment?

  12. Investment Analysts' Weekly Ratings Updates for Myriad GeneticsRead the original story w/Photo

    Feb 9, 2017 | AmericanBankingNews.com

    2/8/2017 - Myriad Genetics had its "hold" rating reaffirmed by analysts at Jefferies Group LLC. They now have a $18.00 price target on the stock. 2/7/2017 - Myriad Genetics had its "neutral" rating reaffirmed by analysts at Piper Jaffray Companies.

    Comment?

  13. Q4 2017 Earnings Forecast for Myriad Genetics, Inc. Issued By Jefferies GroupRead the original story w/Photo

    Feb 9, 2017 | AmericanBankingNews.com

    Myriad Genetics, Inc. - Equities research analysts at Jefferies Group lifted their Q4 2017 earnings per share estimates for Myriad Genetics in a report released on Wednesday. Jefferies Group analyst B. Couillard now forecasts that the brokerage will earn $0.29 per share for the quarter, up from their prior forecast of $0.28.

    Comment?

  14. Myriad Genetics, Inc. (MYGN) Issues FY17 Earnings GuidanceRead the original story w/Photo

    Feb 9, 2017 | Daily Political

    Myriad Genetics, Inc. updated its FY17 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus estimate of $1.00.

    Comment?

  15. Robecosam AG Acquires New Position in Myriad Genetics, Inc.Read the original story w/Photo

    Feb 8, 2017 | Daily Political

    Robecosam AG acquired a new stake in Myriad Genetics, Inc. during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 50,934 shares of the company's stock, valued at approximately $1,054,000.

    Comment?

  16. Myriad Genetics, Inc. (MYGN) Upgraded to Neutral by Ladenburg Thalmann Financial ServicesRead the original story w/Photo

    Feb 8, 2017 | AmericanBankingNews.com

    MYGN has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Myriad Genetics from a "hold" rating to a "sell" rating in a report on Tuesday, October 25th.

    Comment?

  17. Myriad Genetics, Inc. (MYGN) Stock Price Up 7.3% on Earnings BeatRead the original story w/Photo

    Feb 8, 2017 | IntersportsWire

    Myriad Genetics, Inc. rose 7.3% during trading on Wednesday following a better than expected earnings announcement. The company traded as high as $17.89 and last traded at $16.52, with a volume of 6,514,781 shares traded.

    Comment?

  18. Myriad Genetics, Inc. (MYGN) Position Boosted by Rhumbline AdvisersRead the original story w/Photo

    Feb 2, 2017 | Daily Political

    Rhumbline Advisers increased its stake in shares of Myriad Genetics, Inc. by 2.2% during the third quarter, Holdings Channel reports. The firm owned 72,174 shares of the company's stock after buying an additional 1,584 shares during the period.

    Comment?

  19. Myriad Genetics, Inc. (MYGN) Lifted to Hold at Zacks Investment ResearchRead the original story w/Photo

    Feb 1, 2017 | AmericanBankingNews.com

    According to Zacks, "Ahead of its second quarter 2017 report, in the last three months, Myriad's share price trend was neck and neck with respect to that of the Medical-Biomed/Genetics Market trend. However the trend got disturbed post its mixed fiscal 2017 first quarter earnings with earnings missing the Zacks Consensus Estimate and revenues ahead of the mark.

    Comment?

  20. Utilization of biopsy-based genomic classifier to predict distant...Read the original story

    Jan 24, 2017 | Prostate Cancer and Prostatic Diseases

    Brigham and Women’s Cancer Center and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. E-mail: pnguyen@LROC.harvard.edu We examined the ability of a biopsy-based 22-marker genomic classifier to predict for distant metastases after radiation and a median of 6 months of androgen deprivation therapy .

    Comment?